Back to Search
MELANIE ROYCE, MD, PHD
MD, PHD
Internal Medicine Physician
NPI: 1124049366Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
2004-0041(NM)
Research & Publications (20)
The effect of adjuvant radiotherapy on mortality differs according to primary tumor location in women with node-positive breast cancer.
PMID 19330292·Strahlenther Onkol·2009
8-other
Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells.
PMID 19390626·PLoS One·2009
8-other
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
PMID 18773144·Invest New Drugs·2009
3-trial
XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer.
PMID 19002271·Int J Med Sci·2008
3-trial
Idiopathic granulomatous lobular mastitis masquerading as a breast abscess and breast carcinoma.
PMID 17921721·Am J Clin Oncol·2007
5-case
Disparities in cancer care among racial and ethnic minorities.
PMID 17024873·Oncology (Williston Park)·2006
6-review
Prognostic value of nodal ratios in node-positive breast cancer.
PMID 16782931·J Clin Oncol·2006
1-meta
Modeling the effect of age in T1-2 breast cancer using the SEER database.
PMID 16212670·BMC Cancer·2005
8-other
Minimum follow-up time required for the estimation of statistical cure of cancer patients: verification using data from 42 cancer sites in the SEER database.
PMID 15904508·BMC Cancer·2005
8-other
STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis.
PMID 14692019·Cancer·2004
8-other
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.
PMID 14698135·Cytokine·2004
3-trial
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.
PMID 14707494·Invest New Drugs·2004
3-trial
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
PMID 15136595·J Clin Oncol·2004
8-other
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.
PMID 12942555·Cancer·2003
3-trial
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
PMID 12947059·J Clin Oncol·2003
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- UNM CANCER CTR, 1201 CAMINO DE SALUD NE
ALBUQUERQUE, NM 87131 - Phone
- (505) 272-4946
Quick Facts
- NPI
- 1124049366
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile